AzurRx BioPharma initiated at Roth Capital

AzurRx BioPharma initiated with a Buy at Roth Capital. Roth Capital analyst Jerry Isaacson initiated AzurRx BioPharma with a Buy rating and $10.50 price target. In a research note to investors, Isaacson says he assumes MS1819 to treat EPI in CF patients will be approved for the patient population in 2022, and says his model includes pricing starting at $18,000 per patient per year, in line with currently approved PERTs. MS1819 has numerous potential advantages over currently approved treatments, including reduced pill burden, and the fact that it is not derived from an animal source, he adds.
https://thefly.com/landingPageNews.php?id=2853825